Neuspera Medical Unveils Global First Integrated Sacral Neuromodulation System with 77% Gross Margin Potential in Billion-Dollar Urology Market
NeuSpera
Developer of Implantable Medical Devices
Source: Medical Device Distributor Alliance
"
As Medtronic and Boston Scientific engage in fierce competition in the blue ocean of sacral neuromodulation, an industry dark horse makes a strong breakthrough with the world’s first innovative product!
A Duopoly Contention and New Entrants: The Landscape of the Multi-Billion-Dollar Sector Is Quietly Being Reshaped.
"
01
World’s First Integrated Sacral Neuromodulator Launched
Pioneering a New Paradigm in Urinary Incontinence Treatment!
Recently (June 18), U.S. medical device company NeuSpera Medical announced that itsInnovative Integrated Sacral Neuromodulator (ISNM) – NeuSpera, officially approved by the FDA for use inTreatment of Urgency Urinary Incontinence (UUI)。
Regarding the approval of NeuSpera for the treatment of UUI, Dave Van, CEO of NeuSpera, stated:
We are usingThe World’s First Integrated SNM Redefines the Standard of Care for UUI, through this patient-centric intelligent solution, we are committed to eliminating treatment barriers and tangibly improving the quality of life for millions of patients with urgency urinary incontinence (UUI).
So, what exactly makes NeuSpera so impressive that companies are full of confidence in it?
NeuSpera is a highly integrated neuromodulation device consisting of miniature implantable electrodes, a wearable wireless generator, a clinician programmer, and a mobile app.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Neuspera
Compared to similar SNM products currently on the market, itsOffers numerous advantages, including minimal invasiveness, complete elimination of battery-related complications, and intelligent operation., patients need only wear the activation disc around their waist for approximately two hours each day to easily activate the therapeutic function, providing a safer and more effective new option for the clinical treatment of UUI.
NeuSpera’s miniature implantable electrode has a diameter of only 2 mm and a volume of just 0.03 mL; the entire system occupies approximately 75 times less space than other peripheral nerve stimulation (PNS) devices, reflecting its miniaturized product design.Not only can it allow physicians to access more regions of the nervous system than when using larger implants,It also enables the product to be less invasive, resulting in smaller scars and reduced patient discomfort.
Meanwhile, a lightweight wireless transmitter can be directly embedded into customized underwear, allowing patients to receive treatment whileNo need to endure the physical discomfort and aesthetic issues associated with traditional devices, more comfortable and confident during treatment.
Previously, the technical challenge of SNM products lay in battery lifespan, whileNeuSpera’s most core innovation lies in its departure from implanted batteries., the wearable wireless generator can wirelessly charge miniature implanted electrodes deeply embedded in the body, which not only solves the problem of frequent battery replacements required by traditional SNM devices, but also completely avoids complications associated with implantable batteries.
NeuSpera’s mid-field power transfer technology is its core patent. This technology utilizes transient and propagating electromagnetic waves to power implantable medical devices at depths exceeding 10 centimeters. By leveraging the body as a natural waveguide to concentrate energy,Ensure that energy is delivered to the precise target area.
NeuSpera’s intelligence is mainly reflected inPatients can easily adjust treatment settings, control stimulation status, and perform various other functions via the mobile app.
Additionally, it offers an iPad-based clinician programmer that serves as a “command center,” enabling physicians to comprehensively monitor the status of all implanted NeuSpera devices and external wireless transmitters, andAllows physicians to modify patient treatment parameters, adjust electrode configurations, and set stimulation program specifications, facilitating timely optimization of treatment plans.
It is worth noting that as early as April 2023, NeuSpera had already received FDA approval for the treatment of chronic peripheral nerve pain in humans. So, what is the efficacy of this latest approval in the field of sacral nerve stimulation?
In March this year, NeuSpera Medical presented six-month clinical data from its NeuSpera trial at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) annual meeting. The trial included a total of 128 patients with urinary incontinence.Studies have shown that its clinical efficacy is comparable to that of traditional sacral nerve stimulators, while avoiding the discomfort, surgical risks, and cosmetic concerns associated with implanted batteries.
84.2% of implanted patients experienced a ≥50% reduction in urgency urinary incontinence, with efficacy comparable to that reported in recent SNM studies
84% of responders met the criteria for "super response," defined as a >75% reduction in UUI symptoms (patients exhibiting an exceptionally favorable response to specific treatment are classified as "super responders").
42% of responding patients achieved a completely "dry" state (100% elimination of UUI symptoms)
Quality of life index significantly improved by 3.5-fold, with synchronous reductions in urinary frequency and urgency episodes
Clearly, the market launch of NeuSpera will achieve dual breakthroughs in two key dimensions—therapeutic efficacy and patient experience—bringing a disruptive revolution to the global treatment of urgency urinary incontinence (UUI) and poised to establish a new therapeutic paradigm.
02
The "Neural Gold Mine" of Capital Competition
Why Are Sacral Nerves Sparking Billion-Dollar M&A Deals?
Notably, to accelerate NeuSpera’s FDA market approval process,NeuSpera Medical completed its Series D financing last July, successfully raising $23 million (approximately RMB 170 million).，Co-led by Vertex Ventures HC and Treo Ventures, with participation from Olympus Innovation Ventures, Action Potential Venture Capital, and other investors.
Previously, the company completed a $26 million Series B financing round in 2018 and a $65 million Series C financing round in 2021. The continuous capital infusion has not only injected strong momentum into its technological breakthroughs,It further reflects the strategic value of the sacral neuromodulation sector.
In fact, capital’s bets on the sacral nerve modulation sector have long been evident. Last January, the global medical device giantBoston ScientificHigh-profile announcementAcquire Axonics, the leader in the sacral neuromodulation sector, for $3.7 billion in cash (approximately RMB 26.5 billion),A 23.3% premium to its closing price, this transaction amount not only set a record for Boston Scientific, the “M&A powerhouse,” in terms of its total M&A volume over the past two years, but also ranked among the top three in its century-long expansion history.
In the sacral neuromodulation sector, Axonics’ long-standing rival is the medical device giant Medtronic. As early as the late 20th century, when sacral neuromodulation (SNM) technology was emerging, Medtronic entered the market first and even held a monopolistic position for a time.With the acquisition officially finalized last November, Boston Scientific will formally challenge Medtronic.
So, what exactly is the allure of the sacral nerve modulation sector that has sparked fierce competition between the two medical device giants and capital investors?
23.6 Billion Blue Ocean: Aging Drives Explosive Market Growth
Sacral Neuromodulation (SNM)/Sacral Nerve Stimulation (SNS) primarily works by emitting pulsed electrical signals via an implanted sacral nerve stimulator to precisely modulate abnormal sacral reflex arcs, thereby effectively treating urinary dysfunctions such as frequency, urgency, and incontinence caused by overactive bladder (OAB); hence, it is commonly referred to in clinical practice as the "bladder pacemaker."
OAB is a complex cluster of symptoms triggered by conditions such as benign prostatic hyperplasia and neurodegenerative diseases like Parkinson's disease and Alzheimer's disease,16%–29% of the global population (with some studies reporting figures as high as 75%) have been affected by it.。
More critically, 25%–40% of patients respond poorly to first-line (behavioral modification) and second-line (pharmacological therapy) treatment regimens,SNM/SNS technology has been successfully implemented in over 70 countries, benefiting more than 4.25 million patients worldwide, and is recognized as an advanced international treatment for overactive bladder (OAB).
Meanwhile, the global population is aging at an accelerated pace, and the incidence of urinary incontinence in the elderly, caused by bladder atrophy, detrusor muscle aging, and sphincter dysfunction, continues to rise.further driving up the clinical demand for SNM/SNS technology.
According to Mordor Intelligence, the global market size for sacral neuromodulation (also known as sacral nerve stimulation) was $2.28 billion (approximately RMB 16.4 billion) in 2019, pre-It is projected to reach US$3.3 billion (approximately RMB 23.6 billion) by 2027, with an expected compound annual growth rate of 5.5%., this growth not only validates the clinical value of the technology but also paints a grand blueprint for industry participants.
Gross Margin of 77.2%: Sacral Neuromodulation Products Demonstrate Remarkable Profitability
In addition to the vast market potential, the profitability of SNM/SNS-related products is evident.
Taking the industry leader Axonics as an example,It ranked second in the Financial Times’ 2023 list of the fastest-growing companies in the Americas, demonstrating strong growth momentum.
Unlike many companies struggling with operations, Axonics maintained strong growth momentum prior to its acquisition by Boston Scientific. According to its third-quarter 2024 financial report, the company’s net revenue reached $116 million, a 25% year-over-year increase. Revenue from sacral neuromodulation amounted to $92.3 million, accounting for nearly 80% of the company’s total revenue.The company’s overall gross profit margin climbed further to 77.2%.This achievement is attributed to the company's strategic market layout,This is also closely tied to the high profitability of its core product—the sacral neuromodulation system.
Following its successful acquisition by Boston Scientific, the installed base of Axonics’ sacral neuromodulation systems surpassed 5,000 units within just a few months.Directly drove the gross margin of Boston Scientific's urology neuromodulation product line from 68% to 72%.
Axonics’ success has undoubtedly set a profitability benchmark for the industry, serving as an enticement for more companies to enter the sacral neuromodulation sector.
03
Surging Demand, Domestic Breakthrough
Distributors: The Time Is Ripe to Tap into the Sacral Nerve Market!
Turning our attention back to the domestic market,Is the Sacral Neuromodulation Sector in China Worth Distributors’ Investment at Present?
First, in terms of market size, the combination of high prevalence and low penetration rate has laid the foundation for explosive growth in China's sacral neuromodulation sector.
Results from China’s first large-scale epidemiological survey on overactive bladder (OAB) indicate that the overall prevalence of OAB among individuals aged 18 and above is 5.9%, surging to 10% in those aged 40 and older. Meanwhile, the prevalence of urinary incontinence among elderly Asian women reaches 45.1%, ranking highest globally.
Behind the high prevalence lies a potential patient population numbering in the tens of millions; however, the penetration rate of sacral neuromodulation technology in China remains relatively low.This “unmet clinical need” represents a golden opportunity for distributors to strike gold.
Secondly, from the perspective of product supply, domestic technologies have transitioned from catching up to leading the way, ushering in a new era of “domestic substitution.”
With national policy support in the field of neuromodulation, domestic innovative medical device companies are accelerating their breakthroughs in the sacral nerve domain.
In July 2022, China's leading enterprise in neuromodulationPINS Medical Launches China's First Rechargeable Implantable Sacral Nerve Stimulator, ushering in a new era of externally wireless rechargeable sacral nerve stimulators in China.
June 2023,NeuSpera Medical Launches the World’s First 6-Contact Electrode Sacral Neuromodulation System, featuring high-density stimulation electrodes and multiple stimulation combination options, it offers greater precision than traditional devices, provides more stimulation combinations, and is more energy-efficient, thereby extending the battery life of the implant.
The technological leap not only reduces treatment costs for patients but also provides distributors with a differentiated competitive advantage for their market positioning.
Finally, from the demand side, the intensifying aging population and rising household purchasing power will further unleash the demand for high-end medical devices.。
Although China’s sacral neuromodulation sector started later, it has developed extremely rapidly. By 2024, the number of implanted devices had exceeded 6,200 cases, and the sector is poised to become a new growth engine.
High prevalence ignites urgent clinical demand, while domestically produced technologies fortify competitive barriers. Driven by the dual engines of policy incentives and surging demand, China’s sacral neuromodulation sector is accelerating into a “golden period of explosive growth.” For distributors, strategic entry at this juncture is not merely about seizing first-mover advantage, but securing the “last golden seat” in a billion-dollar blue-ocean market.
# China MRI Report
#China CT Report
# China Health and Health Statistical Yearbook
#Survey on the Information Status of Chinese Hospitals
#Medical Ultrasound #Endoscopy #Patient Monitoring #Cardiac Electrophysiology #Rehabilitation #Reproductive Health #Dental Care #Medical Aesthetics #Report on the Home Medical Device Sector......
Reply with the keyword “8888”, you can claim it